CRMD — CorMedix Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1410098 ·
Last close
$8.28
Market Cap
$645.38M
52W High
$9.09
52W Low
$7.10
ADV30
1,264,144
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 127,427,000 | 105,122,000 | 63,658,000 | 38,601,000 | 815,637,000 | 178,087,000 | 378,588,000 |
| Dec 2025 | 128,615,264 | 107,308,042 | 59,126,248 | 14,020,141 | 826,142,000 | 144,837,000 | 420,835,000 |
| Sep 2025 | 104,275,289 | 93,080,673 | 51,345,966 | 108,562,980 | 750,861,478 | 48,493,076 | 376,732,072 |
| Jun 2025 | 39,736,790 | 37,874,342 | 19,543,505 | 19,827,981 | 252,599,103 | 159,308,966 | 31,968,916 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$197,691,000
Investing CF
$-305,270,000
Financing CF
$220,263,000
CapEx
$-2,979,000
Dividends Paid
—
Buybacks
$-11,092,000
EPS Diluted TTM
$2.13
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,974,000
Inventory
$30,731,000
Receivables
$154,807,000
ST Investments
$0
EBIT TTM
$195,802,094
Pretax Income TTM
$185,017,102
Interest Exp TTM
$2,781,999
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$462,248,992
EBITDA
$262,548,000
Free Cash Flow
$178,142,656
Enterprise Value
$529,906,464
Total Cash
$256,692,000
Total Debt
$147,455,008
Shares Out
77,944,324
Trailing EPS
$2.18
Book Value
$5.93
ROE
54.9%
ROA
24.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 311,709,000 | 150,141,000 | 163,055,000 | 826,142,000 | 420,835,000 | — | 175,046,000 |
| Dec 2024 | 43,472,000 | -22,356,000 | -17,930,000 | 118,846,000 | 34,189,000 | — | -50,615,000 |
| Dec 2023 | 0 | -48,957,788 | -46,339,227 | 82,059,957 | 11,917,528 | — | -38,409,480 |
| Dec 2022 | 65,408 | -30,623,968 | -29,701,705 | 62,038,259 | 6,978,523 | — | -24,356,732 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CBIO | CRESCENT BIOPHARMA, INC. | $630.33M | $16.97 | — |
| SGMT | Sagimet Biosciences Inc. | $628.85M | $10.21 | — |
| VSTM | Verastem, Inc. | $621.27M | $6.86 | — |
| EVO | Evotec SE | $671.69M | $1.89 | — |
| ARVN | ARVINAS, INC. | $610.71M | $9.34 | — |
News headlines (Yahoo Finance, 1h cache)
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
2026-08-20 14:14 · Yahoo
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
2026-08-20 13:55 · Yahoo
Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...
2026-08-13 23:08 · Yahoo
CorMedix Q2 Earnings Call Highlights
2026-08-13 15:06 · Yahoo
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
2026-08-13 15:04 · Yahoo
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
2026-08-13 12:45 · Yahoo
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 11:30 · Yahoo
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
2026-06-30 15:07 · Yahoo
CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook
2026-06-17 11:12 · Yahoo
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why
2026-06-16 06:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.